A Phase I Study of LJM716 in Japanese Patients With Advanced Solid Tumors
NCT01911936 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12
Last updated 2020-12-17
Summary
This study will evaluate safety and tolerability to estimate the MTDand/or recommended dose.
Conditions
- Neoplasms
Interventions
- DRUG
-
LM716
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis Pharmaceuticals · Novartis Pharmaceuticals
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-09-30
- Primary Completion
- 2015-03-31
- Completion
- 2015-03-31
Countries
- Japan
Study Locations
More Related Trials
-
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Patients With Advanced or Refractory Solid Tumors or Lymphoma
NCT01962532 ·Status: COMPLETED ·Phase: PHASE1
-
Phase I Study of MK-1496 in Patients With Advanced Solid Tumor (MK-1496-002 AM 4)(COMPLETED)
NCT00880568 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of BKM120 in Adult Japanese Patients With Advanced Solid Tumors
NCT01283503 ·Status: COMPLETED ·Phase: PHASE1
-
Multiple Ascending Dose Study of BMS-754807 in Patients With Solid Tumors in Japan
NCT00898716 ·Status: COMPLETED ·Phase: PHASE1
-
First-in-Human Study of LPM6690176 in Patients With Advanced Solid Tumors.
NCT06240546 ·Status: RECRUITING ·Phase: PHASE1
-
To Assess the Safety, Tolerability and Pharmacokinetics of INCB086550
NCT04674748 ·Status: TERMINATED ·Phase: PHASE1
-
Japanese Phase 1 Study of BMS-844203 (CT322)
NCT01146171 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Study of E7130 in Participants With Solid Tumors
NCT03444701 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I Study of Oral MEK162 in Japanese Patients With Advanced Solid Tumors
NCT01469130 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors
NCT02836600 ·Status: COMPLETED ·Phase: PHASE1
-
KN046 in Subjects With Advanced Solid Tumors and Lymphoma
NCT03733951 ·Status: COMPLETED ·Phase: PHASE1
-
MSB0011359C (M7824) in Participants With Metastatic or Locally Advanced Solid Tumors
NCT02699515 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I Study OfLNF2007 Monotherapy in Patients with Advanced Solid Tumors
NCT06752447 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Phase 1 Study of E7090 in Subjects With Solid Tumor
NCT02275910 ·Status: COMPLETED ·Phase: PHASE1
-
JMT106 Injection in the Treatment of Advanced Solid Tumors
NCT07275073 ·Status: RECRUITING ·Phase: PHASE1
-
Multiple Ascending Dose Study of BMS-907351 (XL184) in Patients With Solid Tumors in Japan
NCT01018745 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in Japan
NCT00503477 ·Status: COMPLETED ·Phase: PHASE1
-
First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors
NCT06877650 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies
NCT04937153 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of E7050 Administered Orally to Patients With Advanced Solid Tumors
NCT00921869 ·Status: COMPLETED ·Phase: PHASE1
-
SMP-3124LP in Adults With Advanced Solid Tumors
NCT06526819 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Dose-escalating Study of LBH589 in Adult Patients With Advanced Solid Tumors
NCT00739414 ·Status: COMPLETED ·Phase: PHASE1
-
An Extension Trial to a Phase I Dose Escalation Study of Gimatecan Administered Orally 5 Consecutive Days to Japanese Patients With Advanced Solid Tumor
NCT00441610 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors
NCT03355066 ·Status: TERMINATED ·Phase: PHASE1
-
Phase 1 Study of DS-8895a in Subjects With Advanced Solid Tumors
NCT02004717 ·Status: COMPLETED ·Phase: PHASE1